Please use this identifier to cite or link to this item:
- Assessment of the In Vivo Genotoxicity of New Lead Compounds to Treat Sickle Cell Disease
- Universidade Estadual Paulista (UNESP)
- Universidade Federal do Rio de Janeiro (UFRJ)
- Fundação para o Desenvolvimento da UNESP (FUNDUNESP)
- Fundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)
- Programa de Apoio ao Desenvolvimento Científico da Faculdade de Ciências Farmacêuticas da UNESP (PADC)
- FAPESP: 10/12495-6
- PADC-FCFar UNESP: 107/10
- The compounds 1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) methyl nitrate (C1), (1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) ethyl nitrate (C2), 3-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) benzyl nitrate (C3), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)-N-hydroxy-benzenesulfonamide (C4), 4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) benzyl nitrate (C5), and 2-[4-(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl) phenyl] ethyl nitrate (C6) were evaluated with a micronucleus test using mouse peripheral blood to identify new candidate drugs for the treatment of sickle cell disease (SCD) that are safer than hydroxyurea. The compounds induced an average frequency of micronucleated reticulocytes (MNRET) of less than six per 1,000 cells at 12.5, 25, 50, and 100 mg/kg, whereas hydroxyurea induced an average MNRET frequency of 7.8, 9.8, 15, and 33.7 per 1000 cells respectively, at the same concentrations. Compounds C1-C6 are new non-genotoxic in vivo candidate drugs for the treatment of SCD symptoms.
- Molecules. Basel: Mdpi Ag, v. 16, n. 4, p. 2982-2989, 2011.
- Mdpi Ag
- genotoxicity assay
- sickle cell
- phthalimide derivatives
- Acesso aberto
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.